Cardiocore raises $8 million in venture funding Former Johnson & Johnson Vice Chairman and recognized life sciences entrepreneur expand Cardiocore’s expertise. Bethesda, Maryland, March 29, 2006 -- Cardiocore Lab, Inc., a premier provider of centralized cardiac safety monitoring and analysis, announced that it has received $8 million in equity financing. This Series A round was co-lead by Caxton Health Holdings and Aperture Venture Partners. Substantial capital was also contributed by The State of Maryland Department of Business and Economic Development. The funds will be used to fuel worldwide expansion of Cardiocore's high-quality cardiac safety services for clinical trials through Europe, Asia, South America, South Africa and Australia. The transaction also adds several industry heavyweights to the Cardiocore team including the former Vice Chairman of a top three pharmaceutical company, and an accomplished life sciences entrepreneur. Robert N. Wilson, Chairman of Caxton Health Holdings and former Vice Chairman of the Board of Directors of Johnson & Johnson, joined Cardiocore as a Special Strategic Advisor. Wilson said, "Cardiocore's management team understands pharmaceutical companies' competitive pressure to execute all aspects of their business efficiently. The company consistently benefits sponsors' drug programs through fast, accurate and complete data delivery." General Partner at Aperture and Chairman of VeriCare, Thomas Cooper, MD, joined Cardiocore's board of directors. He added, "Cardiocore is the ECG core lab best positioned to succeed as drug developers continue to embrace the FDA's E14 guidance for cardiac safety testing. No other provider delivers the right combination of cardiac safety focus, scientific leadership, technological innovation and project management skill." "I am delighted by the support and endorsements Cardiocore has received from Caxton, Aperture and the State of Maryland," commented Cardiocore CEO, Jennifer Cotteleer. "The experience embodied by Bob Wilson, Tom Cooper and their exceptional organizations helps Cardiocore keep raising the bar for core lab quality as we expand our operations around the globe." Cardiocore's board of directors also includes Shiv Tasker (Bluespec CEO), Arthur Rodbell (IXI founder), Vijay Shankaran, MD, PhD (Caxton Health Holdings), and John Krasznekewicz (RusticPartners Managing Partner). The directors have run industry leading organizations in clinical data management, clinical site management, cardiology and financial services. They have founded companies with combined revenues greater than $1 billion. About Cardiocore Cardiocore has provided superior centralized cardiac testing services to the pharmaceutical industry for 13 years. Services include centralized electrocardiographic (ECG) analysis, Holter monitoring, statistical analysis and consulting services such as protocol design. The company is experienced in both design and implementation of Thorough QT Trials as well as cardiac safety and efficacy testing in Phases I, II and III clinical trials. These services are supported by the company's CardioCorrect® system featuring the HolterGateway™ and the CardioPortal™. Cardicore's US headquarters is located in Bethesda, Maryland, and its European subsidiary, Cardiocore Limited, is located in London, England.